Mereo BioPharma (MREO) Current Assets (2017 - 2026)

Mereo BioPharma (MREO) has reported Current Assets for 10 consecutive years, with $33.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 45.62% year-over-year to $33.4 million in Q2 2026; TTM through Jun 2026 was $33.4 million, a 45.62% decrease from a year earlier, with the FY2025 full-year figure at $45.0 million, down 39.78% from the prior year.
• Current Assets was $33.4 million for Q2 2026 at Mereo BioPharma, down from $40.0 million in the prior quarter.
• Over five years, Current Assets peaked at $103.0 million in Q2 2022 and troughed at $33.4 million in Q2 2026.
• A 5-year average of $65.4 million and a median of $65.3 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets surged 38.43% in 2024 and tumbled 45.62% in 2026, its largest moves.
• Over 5 years, Current Assets stood at $72.9 million in 2022, then retreated by 12.51% to $63.8 million in 2023, then climbed by 17.26% to $74.8 million in 2024, then sank by 39.78% to $45.0 million in 2025, then declined by 25.81% to $33.4 million in 2026.
• The last three Current Assets figures came in at $33.4 million (Q2 2026), $40.0 million (Q1 2026), and $45.0 million (Q4 2025), per Business Quant data.